Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to ...

In this week’s edition of InnovationRx, we look at health insurers' vows to improve prior authorization, Bell Labs’ IP ...

Despite Novo Nordisk (NVO) recently ending a partnership with Hims & Hers Health (NYSE:HIMS) to distribute its weight-loss ...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novo Nordisk A/S ("Novo Nordisk" or "the Company") (NYSE: NVO) ...

Berger Montague investigates Hims and Hers after stock drops 26% following Novo Nordisk's termination of GLP-1 drug partnership.

Compounded weight loss drugs have been mostly off the market for about a month, but the weight loss drug industry remains as unsettled as ever.

Novo Nordisk NVO announced that it has ended its collaboration with telehealth provider Hims & Hers Health. In addition, the ...

President Trump declared Iran’s nuclear enrichment facilities “obliterated” over the weekend, but new reports say the damage ...

A unique business structure gives LifeMD access to the growing GLP-1 marketplace that can help boost the heavily shorted stock price. Read an analysis of LFMD here.

Hims & Hers Health will continue offering low-cost compounded weight-loss shots even after Novo Nordisk terminated their ...

The Law Offices of Frank R. Cruz announces an investigation of Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO) on behalf of investors concerning the Company's possible violations of ...

Novo Nordisk A/S has scrapped a partnership with Hims & Hers Health Inc after less than two months, saying the US company is ...